Lapatinib

Catalog No.S2111

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 143 In stock
USD 110 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Lapatinib Chemical Structure

Lapatinib Chemical Structure
Molecular Weight: 581.06

Validation & Quality Control

Cited by 37 publications:

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Lapatinib is available in the following compound libraries:

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Gefitinib (ZD1839) Approved by FDA for NSCLC.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area

Product Description

Biological Activity

Description Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Targets ErbB2 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
ErbB4 [1]
(Cell-free assay)
c-Src [1]
(Cell-free assay)

 View  More

IC50 9.2 nM 10.8 nM 367 nM 3.5 μM
In vitro Lapatinib weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1648MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnTTWM2OD1yLkCyOVQ1KM7:TR?=MnfnV2FPT0WU
HCC2218MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\oTWM2OD1yLkC1N|I3KM7:TR?=Mli3V2FPT0WU
OCUB-MMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXVSmNIUUN3ME2wMlA2PzRizszNNGjUdIxUSU6JRWK=
ECC12NFLNWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXXTWM2OD1yLkC5NlMyKM7:TR?=MUDTRW5ITVJ?
DSH1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlK5TWM2OD1yLkC5N|k3KM7:TR?=NFP3OWZUSU6JRWK=
BT-474MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoX2TWM2OD1yLkKxN|E2KM7:TR?=Mm\NV2FPT0WU
BB30-HNCM1P2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTQTWM2OD1yLkK0OlU1KM7:TR?=M3\V[nNCVkeHUh?=
EKVXM1fHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnyOHJKSzVyPUCuOFQ5PzRizszNNFTZbnBUSU6JRWK=
TE-12M1jJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTBwNEmwOVch|ryPMVrTRW5ITVJ?
A388NFTOcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\hTWM2OD1yLkeyNlU5KM7:TR?=MX;TRW5ITVJ?
TE-9M1XGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjFTWM2OD1yLke0OFU{KM7:TR?=NILJU4ZUSU6JRWK=
LB2241-RCCM17TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nkc2lEPTB;MT6xOVQxOyEQvF2=MlP0V2FPT0WU
LB996-RCCM{fUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTFwM{[yNlgh|ryPMU\TRW5ITVJ?
LC-1FM3fN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTXS|hKSzVyPUGuN|gzPDRizszNNUDnU4F7W0GQR1XS
TE-6NX\ySpppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrXWJhKSzVyPUGuOVUzODFizszNMWLTRW5ITVJ?
A253NHX6bopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3ToO2lEPTB;MT65O|M{PSEQvF2=MYrTRW5ITVJ?
OS-RC-2NH3OZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\oTWM2OD1zLkm5NVk6KM7:TR?=NWr1PWJvW0GQR1XS
TE-1NIL0[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHWTWM2OD1{LkC0PFMh|ryPM1\KTHNCVkeHUh?=
RL95-2NE\aOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDUVpRVUUN3ME2zMlE2PjdizszNNWLaemg4W0GQR1XS
LS-513NEXPO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fFTmlEPTB;Mz60NFA1OSEQvF2=MnTDV2FPT0WU
DJM-1NYnKc5pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTNwNE[5O|Uh|ryPNWnhUXo2W0GQR1XS
NMC-G1NGnkdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4L3RWlEPTB;Mz61OFUxOSEQvF2=NV3oV29KW0GQR1XS
TE-10NIH1R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX3RVRvUUN3ME2zMlU2OzV4IN88US=>M2PBWnNCVkeHUh?=
TE-5NEDHeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTRwMEO3N{DPxE1?NVvBboxVW0GQR1XS
TK10NVvCfll6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTRwMU[1NlIh|ryPM3vsSHNCVkeHUh?=
UACC-812M1ywRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\mR2lEPTB;ND61OlE2OyEQvF2=M2TaWXNCVkeHUh?=
SW962M{L6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljtTWM2OD13LkCyNVU6KM7:TR?=MVXTRW5ITVJ?
SW954MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{eyTGlEPTB;NT6zPVI1PSEQvF2=MkPPV2FPT0WU
COLO-668M2jlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDScmZKSzVyPUWuO|I3PjdizszNM3\FW3NCVkeHUh?=
LB1047-RCCNUPoTJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;XTWM2OD13LkiwNFQ3KM7:TR?=MUfTRW5ITVJ?
NB5MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fhTGlEPTB;Nj6yNVAxOSEQvF2=M2jpcnNCVkeHUh?=
NTERA-S-cl-D1NH3uZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvEVpRKSzVyPU[uNlY2PjFizszNM2jIdXNCVkeHUh?=
IST-MEL1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHi5RnhKSzVyPU[uOFM3QTRizszNNGCy[G9USU6JRWK=
GI-1MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PRUWlEPTB;Nj61NVY5OiEQvF2=MX7TRW5ITVJ?
TGBC1TKBMojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\nZoJKSzVyPUeuNFcyQDNizszNNHzPbXpUSU6JRWK=
GT3TKBNYC1VoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3vTYo4UUN3ME23MlIzPzR2IN88US=>M4D6R3NCVkeHUh?=
EVSA-TNH;MV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfwS|NQUUN3ME23MlQzQDFzIN88US=>MVzTRW5ITVJ?
D-502MGNULJ[Jd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTdwNEi4PVQh|ryPMkniV2FPT0WU
TE-8M2\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjJSo1KSzVyPUeuO|YyPTlizszNMXnTRW5ITVJ?
OVCAR-4M4D1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljYTWM2OD17LkGxOlc2KM7:TR?=MX\TRW5ITVJ?
D-336MGM{Kxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHVTWM2OD17LkS3N|k2KM7:TR?=M3PV[nNCVkeHUh?=
GCIYM2f0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3m2c2lEPTB;OT61O|QzKM7:TR?=MlTsV2FPT0WU
KS-1M3uwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLITWM2OD17Lk[2Nlg4KM7:TR?=NIDRd49USU6JRWK=
HCC2998NW\tbJdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rNTGlEPTB;OT65OlMxPyEQvF2=NYjZOYxNW0GQR1XS
D-247MGNFrZWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzqVnNKSzVyPUmuPVgzQTFizszNNIn6XoJUSU6JRWK=
TE-15NH7heoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzpbllKSzVyPUGwMlI1PSEQvF2=NWD0UI1YW0GQR1XS
IST-MES1Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NECyfWFKSzVyPUGwMlI2PjVizszNNHu2TZVUSU6JRWK=
ETK-1NFP3N3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nNRWlEPTB;MUCuOlI{KM7:TR?=M1\iSHNCVkeHUh?=
RCC10RGBM1[xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnGwTWM2OD1zMD65OlEh|ryPNHm1bmtUSU6JRWK=
KNS-42MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnuxTWM2OD1zMT63NlU2KM7:TR?=MnrVV2FPT0WU
LB771-HNCNX\iU5MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF{LkG3NVIh|ryPNFHKZY9USU6JRWK=
SRNXyzZoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITI[XNKSzVyPUGyMlIxPjRizszNNYrHZlA{W0GQR1XS
NCI-H1355NX;nW29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rsWWlEPTB;MUKuPFk5PSEQvF2=MUHTRW5ITVJ?
ES6MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HhS2lEPTB;MUOuNFc5KM7:TR?=MoTOV2FPT0WU
SK-NEP-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTF|LkK1O|ch|ryPNX;SPJloW0GQR1XS
D-392MGMmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLSWXRnUUN3ME2xN{43PDJ6IN88US=>MV\TRW5ITVJ?
NB7NHzlXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLnS4p[UUN3ME2xOE4zOzd2IN88US=>NEi0R4tUSU6JRWK=
SK-LMS-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nkZ2lEPTB;MUSuOVE1PSEQvF2=NWnYVJRYW0GQR1XS
SK-UT-1MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fKWmlEPTB;MUSuO|g5QSEQvF2=M2LPNHNCVkeHUh?=
CA46NFfmWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF3LkC1PFYh|ryPNELaTm1USU6JRWK=
IST-SL2NX7Yc|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTF3LkG5NFEh|ryPMnPxV2FPT0WU
BC-1NY\0SINiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vXWmlEPTB;MUWuN|MyPCEQvF2=NELaXGNUSU6JRWK=
LS-123M4TsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m0OWlEPTB;MUWuPFE4OyEQvF2=NXrxfpdGW0GQR1XS
Ramos-2G6-4C10NGP5U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGD4dmRKSzVyPUG2MlA6OjRizszNMlHUV2FPT0WU
MZ1-PCMnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrjfI9KSzVyPUG2Mlc{OTNizszNM{nLWHNCVkeHUh?=
LB647-SCLCMn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqwbXJ2UUN3ME2xOk46Ozd{IN88US=>MoL0V2FPT0WU
NCI-H1694NVHLSXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF5LkG1Nlkh|ryPM4\wfnNCVkeHUh?=
NCI-H322MMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDleJNKSzVyPUG3MlQ{PjZizszNMWHTRW5ITVJ?
ES7NH;HUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXj6bHBOUUN3ME2xPE4{QTF2IN88US=>NFf6OXZUSU6JRWK=
LC-2-adMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHwWphKSzVyPUG4MlQ{QDZizszNM1vjV3NCVkeHUh?=
SF268MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\sWGlEPTB;MUiuO|QxQSEQvF2=MkDDV2FPT0WU
RPMI-8402NInrWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn22TWM2OD1zOT6wO|QzKM7:TR?=MVLTRW5ITVJ?
HCE-TM2XX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTJyLkKzOFQh|ryPMoTZV2FPT0WU
A101DNYmxOHZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33HcmlEPTB;MkCuPFU5PyEQvF2=MXHTRW5ITVJ?
MRK-nu-1NGjFe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:5TWM2OD1{MD65NVMh|ryPMVfTRW5ITVJ?
LXF-289MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjQR5Q4UUN3ME2yNU4xOzhizszNMkS2V2FPT0WU
NALM-6MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\UT3NKSzVyPUKxMlE6PjdizszNNULvT2xWW0GQR1XS
DOHH-2NIK1ZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXtTWM2OD1{MT60PFE{KM7:TR?=MVnTRW5ITVJ?
EW-16MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnDTWM2OD1{Mj6xOFAzKM7:TR?=Mmr4V2FPT0WU
A4-FukNXnsN3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HIfmlEPTB;MkKuNlE1QSEQvF2=NUP5W5JNW0GQR1XS
HD-MY-ZNHPp[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT3NnJKSzVyPUKyMlM6PjVizszNM13yPXNCVkeHUh?=
SKM-1NYLNNHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTJ{LkezOVEh|ryPMkW4V2FPT0WU
DMS-153M3LZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTJ|LkSyNFQh|ryPNGTRTpBUSU6JRWK=
LB373-MEL-DM4HybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTKTWM2OD1{Mz61OFUzKM7:TR?=MYrTRW5ITVJ?
LP-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJ|LkiwPVch|ryPNXLjbmhlW0GQR1XS
GI-ME-NNVPjbIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDOc2xKSzVyPUK0MlI6OiEQvF2=MkC1V2FPT0WU
MPP-89MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj3[2EzUUN3ME2yOU4zODN4IN88US=>MYHTRW5ITVJ?
U-698-MM1rwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJ3LkK1NFMh|ryPNWPFRYhqW0GQR1XS
HC-1NYHMV2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\jVGlEPTB;MkWuOlQyQCEQvF2=MojTV2FPT0WU
HCC2157M1;pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJ3Lk[3N{DPxE1?M2PzOnNCVkeHUh?=
MOLT-4M3\5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH63UGpKSzVyPUK2MlI4OyEQvF2=MoXvV2FPT0WU
LS-411NNEPUfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1myNWlEPTB;Mk[uN|M3QSEQvF2=M1i5NnNCVkeHUh?=
BeckerMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjSZlVKSzVyPUK2MlUyQDFizszNMXTTRW5ITVJ?
NCI-H23NWDXU5RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfLNVBKSzVyPUK2Mlc2PzVizszNNGLwPHZUSU6JRWK=
IST-SL1M4XqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPu[VdnUUN3ME2yO{4{QDZ5IN88US=>NFzIXohUSU6JRWK=
MZ2-MELNH7wTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmiwTWM2OD1{Nz60OVY3KM7:TR?=NWTrOFNqW0GQR1XS
RKONILpfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTJ6LkG0OFYh|ryPMUDTRW5ITVJ?
TE-441-TNIrkNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTJ6Lke4PUDPxE1?MV7TRW5ITVJ?
EW-24Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DuT2lEPTB;MkmuNVI2QSEQvF2=MXPTRW5ITVJ?
no-10M2jXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLtR|VKSzVyPUK5MlE3OzFizszNMUXTRW5ITVJ?
D-542MGM1;tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrZTWM2OD1{OT65NlIyKM7:TR?=M4S5[HNCVkeHUh?=
ST486M176Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXxS4hoUUN3ME2zNE43PDVzIN88US=>NWHZNZlwW0GQR1XS
KURAMOCHIMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XrfGlEPTB;M{CuPFA2PyEQvF2=M1rPNnNCVkeHUh?=
ES8NX;LVJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn20TWM2OD1|MT61PVczKM7:TR?=NVz2TY51W0GQR1XS
BL-41MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTN{LkGwOVQh|ryPM{PEWXNCVkeHUh?=
NB6MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTN{LkO4OVUh|ryPMmPNV2FPT0WU
NCI-H1304MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE[ye2VKSzVyPUOyMlQ6PjdizszNM{PmUnNCVkeHUh?=
MS-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvKd5F3UUN3ME2zNk44PzVzIN88US=>MoDEV2FPT0WU
MFH-inoMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7K[4ZJUUN3ME2zOE4{OjJ2IN88US=>NVTQemRmW0GQR1XS
NOS-1MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULFSFFJUUN3ME2zOE43PzR6IN88US=>M3;UWnNCVkeHUh?=
HUTU-80NXj1Uox{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGn4UpVKSzVyPUO1MlM3PjdizszNM2TBbnNCVkeHUh?=
EB2M1LEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTN4Lk[xPFkh|ryPNV\PdmJoW0GQR1XS
L-540NUi2RVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTN5LkKzNFgh|ryPM2PSRXNCVkeHUh?=
NCI-H747NGH0bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvoc21KSzVyPUO4Mlg5PDZizszNNXH5bYhUW0GQR1XS
NCI-H446NWW3cHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrCTWM2OD1|OT65OlUyKM7:TR?=M3TqUHNCVkeHUh?=
MOLT-16M3nmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHicnNKSzVyPUSyMlQyPSEQvF2=M2Kx[XNCVkeHUh?=
BC-3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\lTWM2OD12NT60PFk3KM7:TR?=M1fRW3NCVkeHUh?=
SJSA-1NH;IeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4S2WWlEPTB;NEWuOVQ4PCEQvF2=NVPrZ414W0GQR1XS
BB65-RCCNGnzeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmS2TWM2OD12NT62OlYh|ryPNXTF[Gs6W0GQR1XS
SNB75NXTKfHZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLNU2FKSzVyPUS2MlAyQCEQvF2=M1zKN3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Lapatinib (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro kinase assays The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.

Cell Assay: [1]

Cell lines HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2 cells
Concentrations Dissolved in DMSO, final concentrations ~100 μM
Incubation Time 72 hours
Method Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.

Animal Study: [1]

Animal Models CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
Formulation Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)
Dosages ~100 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Rusnak DW, et al. Mol Cancer Ther, 2001, 1(2), 85-94.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua H  ...more Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02650752 Recruiting Metastatic Breast Cancer|Central Nervous System (CNS) Metastases Memorial Sloan Kettering Cancer Center|Queens Cancer Cent  ...more Memorial Sloan Kettering Cancer Center|Queens Cancer Center of Queens Hospital|University of Michigan January 2016 Phase 1
NCT02581124 Completed Anemia of Chronic Kidney Disease Akros Pharma Inc. October 2015 Phase 1
NCT02559778 Recruiting Neuroblastoma Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Beca  ...more Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals September 2015 Phase 1
NCT02422199 Active, not recruiting HER2 Positive Metastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. May 2015 Phase 1|Phase 2

view more

Chemical Information

Download Lapatinib SDF
Molecular Weight (MW) 581.06
Formula

C29H26ClFN4O4S

CAS No. 231277-92-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms GW-572016, GSK572016
Solubility (25°C) * In vitro DMSO 100 mg/mL (172.09 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,di4-methylbenzenesulfonate

Frequently Asked Questions

  • Question 1
    If I want to use this compound(S2111, Lapatinib) in tumor-bearing mice via injection, how could I prepare the solution?

    Answer: For I.P. administration, the compound solution should be clear solution. S2111 Lapatinib can be dissolved in 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 10 mg/ml for clear solution.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Lapatinib | Lapatinib ic50 | Lapatinib price | Lapatinib cost | Lapatinib solubility dmso | Lapatinib purchase | Lapatinib manufacturer | Lapatinib research buy | Lapatinib order | Lapatinib mouse | Lapatinib chemical structure | Lapatinib mw | Lapatinib molecular weight | Lapatinib datasheet | Lapatinib supplier | Lapatinib in vitro | Lapatinib cell line | Lapatinib concentration | Lapatinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us